Ivana Verlinden

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Treatment of BRAFV600E-mutant melanoma by small molecule inhibitors that target BRAFV600E or MEK kinases is increasingly used in clinical practice and significantly improve patient outcome. However, patients eventually become resistant and therapeutic improvement is required. Molecular diversity within individual tumors (intratumor heterogeneity) and(More)
  • 1